NBTX

Nanobiotix ADR

31.37

Oct 30 • 3:59 PM ET -2.43 (-7.19%)

31.37

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology France Small NASD

Peers: DRTS BCAX KURA REPL TLX PDSB IMTX CGEM JNJ LNTH

| Held by: APIE

Scroll to Statements

Index	-
Market Cap	1.60B
Enterprise Value	1.59B
Income	-61.66M
Sales	9.75M
Book/sh	-0.75
Cash/sh	2.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	97
IPO	Dec 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	163.93
P/B	-
P/C	12.61
P/FCF	-
EV/EBITDA	-
EV/Sales	163.43
Quick Ratio	1.44
Current Ratio	1.44
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.27
EPS next Y	-0.22
EPS next Q	-
EPS this Y	-5.10%
EPS next Y	63.86%
EPS next 5Y	-
EPS past 3/5Y	30.98% 18.47%
Sales past 3/5Y	- 257.86%
EPS Y/Y TTM	-58.83%
Sales Y/Y TTM	-
EPS Q/Q	-559.84%
Sales Q/Q	-84.39%
Earnings	Sep 24 AMC
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	18.09%
Insider Trans	0.00%
Inst Own	0.33%
Inst Trans	5.43%
ROA	-61.74%
ROE	-
ROIC	-131.02%
Gross Margin	-
Oper. Margin	-392.06%
Profit Margin	-632.55%
SMA20	19.27%
SMA50	-3.56%
SMA200	-7.31%
Trades

Shs Outstand	50.80M
Shs Float	41.73M
Short Float	0.47%
Short Ratio	1.33
Short Interest	0.20M
52W High	57.14 -45.10%
52W Low	17.37 80.60%
Volatility	5.75% 6.46%
ATR (14)	2.19
RSI (14)	55.43
Beta	0.88
Rel Volume	1.60
Avg Volume	147.76K
Volume	235,694

Perf Week	6.85%
Perf Month	12.44%
Perf Quarter	-19.34%
Perf Half Y	-10.68%
Perf YTD	35.68%
Perf Year	70.12%
Perf 3Y	394.79%
Perf 5Y	200.77%
Perf 10Y	-
Recom	1.25
Target Price	55.66
Prev Close	33.80
Price	31.37
Change %	-7.19%

Consensus

Strong Buy

Avg. Price Target

$55.66

Implied Upside

+77.4%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 15, 2026	Resumed	GGuggenheim	Buy	$64	+104.0%
Feb 06, 2026	Initiated	TTD Cowen	Buy
Aug 28, 2024	Initiated	GGuggenheim	Buy	$12	-61.7%
Dec 08, 2023	Initiated	LLeerink Partners	Outperform	$11	-64.9%
Jan 06, 2021	Initiated	EEvercore ISI	Outperform

Oct-26-26 11:35AM	Nanobiotix stock gains on positive melanoma trial data (Investing.com) +7.39%
Nov-24-25 10:29AM	Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue (Motley Fool) +5.11%
Oct-07-25 08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire) -7.95%
Jul-07-25 04:15PM	NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) (GlobeNewswire) +13.37%
Jun-10-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
02:00AM	Loading…
May-28-25 02:00AM	NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference (GlobeNewswire) +5.42%
May-21-25 04:15PM	Nanobiotix Provides First Quarter 2025 Operational and Financial Update (GlobeNewswire)
May-14-25 02:00AM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-12-25 02:00AM	Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-05-25 02:00AM	Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer (GlobeNewswire) +5.96%
Apr-30-25 02:00AM	Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call (GlobeNewswire) +7.66%
Apr-14-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Apr-03-25 04:24PM	Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
Apr-02-25 04:15PM	NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire) -5.03%
Mar-31-25 02:00AM	NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 (GlobeNewswire)
04:15PM	Loading…
Mar-27-25 04:15PM	Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC (GlobeNewswire)
Mar-20-25 04:15PM	NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference (GlobeNewswire)
Mar-17-25 04:15PM	NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 (GlobeNewswire) +18.51%
Mar-13-25 05:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -6.97% +5.70%
Feb-12-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jan-29-25 04:15PM	Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 (GlobeNewswire)
Jan-21-25 02:30AM	NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer (GlobeNewswire) +7.26%
Jan-09-25 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-17-24 04:15PM	NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 (GlobeNewswire)
Dec-11-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-09-24 04:15PM	NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer (GlobeNewswire) +9.67%
Nov-13-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Nov-12-24 02:30AM	NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms (GlobeNewswire)
Oct-31-24 03:30AM	NANOBIOTIX to Participate in Multiple Investor Conferences in November (GlobeNewswire)
Oct-11-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
04:15PM	Loading…
Sep-18-24 04:15PM	NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results (GlobeNewswire) +7.91%
Sep-04-24 04:15PM	NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth (GlobeNewswire)
Sep-03-24 04:15PM	Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -12.17%
Aug-08-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jul-09-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jun-12-24 04:15PM	NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 (GlobeNewswire) -8.12%
Jun-11-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Jun-02-24 10:00AM	Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Na ve or Resistant to Prior anti-PD-1 Therapy (GlobeNewswire)
May-28-24 04:15PM	NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call (GlobeNewswire)
May-23-24 04:15PM	NANOBIOTIX to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +6.27%
May-22-24 02:00AM	NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update (GlobeNewswire) -12.52%
May-21-24 04:15PM	Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth (GlobeNewswire)
May-16-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-15-24 04:15PM	NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 (GlobeNewswire)
May-14-24 04:15PM	NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer (GlobeNewswire) +6.42%
Apr-24-24 04:40PM	NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-17-24 04:15PM	NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 (GlobeNewswire)
Apr-13-24 10:02AM	11 Best Nanotechnology Stocks To Invest In (Insider Monkey)
Apr-10-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +6.49%
Apr-02-24 04:15PM	Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation (GlobeNewswire)
Mar-06-24 04:15PM	Nanobiotix to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-13-24 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -6.16%
Jan-31-24 04:15PM	Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:02AM	Baillie Gifford Bolsters Stake in Nanobiotix SA (GuruFocus.com)
Jan-29-24 04:15PM	Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study (GlobeNewswire)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-11-24 04:32PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-26-23 02:00AM	Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets (GlobeNewswire)
Dec-13-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Dec-04-23 04:22PM	Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation JJDC, Inc. (GlobeNewswire)
Nov-13-23 04:15PM	NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update (GlobeNewswire)
Nov-09-23 04:15PM	NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023 (GlobeNewswire)
Nov-08-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Nov-07-23 04:01PM	NANOBIOTIX Announces Closing of Global Offering (GlobeNewswire)
Nov-06-23 02:00AM	NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M (GlobeNewswire)
Nov-02-23 10:49AM	NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M (GlobeNewswire) -14.01%
Nov-01-23 06:32PM	NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant (GlobeNewswire) -8.00%
Oct-23-23 02:00AM	NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023 (GlobeNewswire)
Oct-11-23 04:27PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
Oct-04-23 04:30PM	Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months (GlobeNewswire) -14.35%
Sep-29-23 04:15PM	NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology (GlobeNewswire) +5.04% +5.06%
Sep-28-23 04:15PM	NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer (GlobeNewswire)
Sep-26-23 04:15PM	NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023 (GlobeNewswire)
Sep-19-23 04:15PM	Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023 (GlobeNewswire) -10.85%
Sep-13-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +5.35%
Sep-05-23 04:15PM	NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer (GlobeNewswire)
Aug-31-23 04:15PM	NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 04:15PM	NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3 (GlobeNewswire) -6.08%
Aug-04-23 04:15PM	NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023 (GlobeNewswire) +8.89%
Jul-20-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +10.61% +17.52%
Jul-19-23 04:15PM	NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers (GlobeNewswire)
Jul-10-23 02:00AM	NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3 (GlobeNewswire) +24.52%
Jun-08-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire)
May-17-23 04:15PM	NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update (GlobeNewswire) -7.24%
May-05-23 01:30AM	NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company (GlobeNewswire) +229.05%
Apr-24-23 07:33PM	NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire) +14.43% -39.95%
Apr-17-23 04:15PM	NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023 (GlobeNewswire)
Apr-11-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -5.31%
Mar-27-23 04:15PM	Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call (GlobeNewswire)
Mar-14-23 04:15PM	Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023 (GlobeNewswire) +8.88% -8.71%
Feb-14-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +5.99% -7.29%
Jan-11-23 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) -6.49% +12.47%
Dec-27-22 01:45AM	NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer (GlobeNewswire) -5.75%
Dec-21-22 04:15PM	NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement (GlobeNewswire)
Dec-08-22 04:15PM	Voting Rights and Shares Capital of the Company (GlobeNewswire) +5.76%
Nov-15-22 04:15PM	NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -8.88%
Nov-14-22 04:15PM	NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer (GlobeNewswire) +7.89%
Nov-10-22 08:28AM	Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients (Benzinga)
02:00AM	NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Nov-09-22 04:15PM	NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update (GlobeNewswire)

Show Previous News

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Levy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Co-FounderDr. Laurent Levy Ph.D.

Chief People Officer & Member of Executive BoardMs. Anne-Juliette Hermant M.A.

Chief Medical Officer & Member of Executive BoardDr. Louis Kayitalire M.D.

Co-FounderMr. Earl J. Bergey Ph.d.

CFO & Member of Executive BoardMr. Arnd Christ MBA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NBTX

Nanobiotix ADR

Upgrade your Finviz experience